CoChat

Protective efficacy of Toxoplasma gondii GRA12 or GRA7 recombinant proteins encapsulated in PLGA nanoparticles against acute Toxoplasma gondii infection in mice

Open access
Sun, Hong-chao, Deng, Pu-ming, Fu, Yuan, Deng, Jin-hua, Xie, Rong-hui, Huang, Jing, Qi, Meng, Shi, Tuan-yuan · 2023 · Frontiers in Cellular and Infection Microbiology

The DOI matches its Crossref record; 58 of the 61 references it cites were found in a registry or an index; 2 of the 8 sources its claims cite were checked for support.

Abstract

Background: Toxoplasma gondii is an apicomplexan parasite that affects the health of humans and livestock, and an effective vaccine is urgently required. Nanoparticles can modulate and improve cellular and humoral immune responses. Methods: In the current study, poly (D, L-lactic-co-glycolic acid) (PLGA) nanoparticles were used as a delivery system for the T. gondii dense granule antigens GRA12 and GRA7. BALB/c mice were injected with the vaccines and protective efficacy was evaluated. Results: Mice immunized with PLGA+GRA12 exhibited significantly higher IgG, and a noticeable predominance of IgG2a over IgG1 was also observed. There was a 1.5-fold higher level of lymphocyte proliferation in PLGA+GRA12-injected mice compared to Alum+GRA12-immunized mice. Higher levels of IFN-g and IL-10 and a lower level of IL-4 were detected, indicating that Th1 and Th2 immune responses were induced but the predominant response was Th1. There were no significant differences between Alum+GRA7-immunized and PLGA+GRA7-immunized groups. Immunization with these four vaccines resulted in significantly reduced parasite loads, but they were lowest in PLGA+GRA12-immunized mice. The survival times of mice immunized with PLGA+GRA12 were also significantly longer than those of mice in the other vaccinated groups. Conclusion: The current study indicated that T. gondii GRA12 recombinant protein encapsulated in PLGA nanoparticles is a promising vaccine against acute toxoplasmosis, but PLGA is almost useless for enhancing the immune response induced by T. gondii GRA7 recombinant protein.

Overview

CoChat Summary

## TL;DR

This mouse study tested recombinant Toxoplasma gondii GRA12 or GRA7 proteins delivered in PLGA nanoparticles versus alum or controls. PLGA-encapsulated GRA12 performed best, inducing stronger immune responses, lower parasite burdens, and longer survival after acute RH strain challenge.

## Key findings

  • PLGA+GRA12 induced the strongest antibody response, with significantly higher IgG than Alum+GRA12 and a predominance of IgG2a over IgG1; the paper reports IgG2a was higher than IgG1 in the PLGA+GRA12 group and that IgG2a was higher there than in all other vaccine groups.
  • Lymphocyte proliferation in PLGA+GRA12 was about 1.54-fold higher than in Alum+GRA12.
  • In splenocyte cultures, PLGA+GRA12 produced 2030.50 pg/mL IFN-γ, compared with 1133.14 pg/mL in Alum+GRA12; PLGA+GRA7 had 1219.44 pg/mL vs 898.31 pg/mL in Alum+GRA7, with no significant difference.
  • After challenge, parasite loads were significantly reduced in all vaccinated groups, but PLGA+GRA12 was lowest; relative to Alum+GRA12, PLGA+GRA12 had parasite loads 3.08-fold lower in heart, 2.49-fold lower in liver, 3.16-fold lower in lung, and 6.30-fold lower in spleen.
  • Survival after RH strain challenge was longest in PLGA+GRA12: mean survival time 14.5 days, versus 9.5 days for Alum+GRA12; control mice died by 4.5 days.

## Methods

  • Experimental vaccine study in female BALB/c mice, aged 6–8 weeks, with 13 mice per group; eight groups included PLGA-NPs-GRA7, PLGA-NPs-GRA12, Alum-GRA7, Alum-GRA12, Alum alone, PLGA alone, PBS, and an unimmunized group.
  • Recombinant GRA7 and GRA12 proteins were produced, encapsulated in PLGA nanoparticles using a water/oil/water solvent evaporation method, and characterized by TEM and dynamic light scattering; reported mean diameters were 106.0 ± 22.1 nm for PLGA+GRA12 and 130.8 ± 27.1 nm for PLGA+GRA7.
  • Mice received three intraperitoneal immunizations at 14-day intervals; 5 weeks after the last immunization, subsets were tested for IgG/IgG1/IgG2a ELISA, splenocyte proliferation, cytokines (IFN-γ, IL-4, IL-10), qPCR parasite burden, and Kaplan–Meier survival after challenge with 1 × 10^3 RH tachyzoites.

## Limitations

  • The authors explicitly note that one candidate antigen may induce only partial protective immunity, and that a combined vaccine including multiple parasite life stages may be needed for complete protection.
  • They also state that it would be informative to evaluate PLGA+GRA12 in low-virulence T. gondii strains in future experiments.
  • Evident from the text: the study assessed protection only in BALB/c mice against the acute RH strain challenge, so broader strain- or host-generalizability is not established.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fcimb.2023.1209755

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 SDS-PAGE and western blotting analysis of T. gondii GRA7 and GRA12 recombinant proteins. (A) SDS-PAGE analysis of recombinant T. gondii GRA7 protein purified via Ni-NTA purification agarose. (B) Western blotting analysis of recombinant T. gondii GRA7-pET-32a protein. (C) SDS-PAGE analysis of recombinant T. gondii GRA12 protein purified via Ni-NTA purification agarose. (D) Western blotting analysis of recombinant T. gondii GRA12 pET-32a protein. The left band represents pET-32a, and the right band represents the recombinant T. gondii GRA12- pET-32a.
Figure 1 SDS-PAGE and western blotting analysis of T. gondii GRA7 and GRA12 recombinant proteins. (A) SDS-PAGE analysis of recombinant T. gondii GRA7 protein purified via Ni-NTA purification agarose. (B) Western blotting analysis of recombinant T. gondii GRA7-pET-32a protein. (C) SDS-PAGE analysis of recombinant T. gondii GRA12 protein purified via Ni-NTA purification agarose. (D) Western blotting analysis of recombinant T. gondii GRA12 pET-32a protein. The left band represents pET-32a, and the right band represents the recombinant T. gondii GRA12- pET-32a.CC BY · PubMed Central
Figure 2 Sizes and distributions of recombinant T. gondii GRA7 and GRA12 proteins encapsulated in PLGA NPs as observed via TEM. (A) PLGA+GRA7 NPs (10,000x, scale bar = 1 μm.) (B) PLGA+GRA12 NPs (10,000x, scale bar = 1 μm).
Figure 2 Sizes and distributions of recombinant T. gondii GRA7 and GRA12 proteins encapsulated in PLGA NPs as observed via TEM. (A) PLGA+GRA7 NPs (10,000x, scale bar = 1 μm.) (B) PLGA+GRA12 NPs (10,000x, scale bar = 1 μm).CC BY · PubMed Central
Figure 3 Release characteristics of T. gondii GRA7 and GRA12 proteins using PLGA NPs as a delivery system. Data represent mean ± SD, n = 3 experiments.
Figure 3 Release characteristics of T. gondii GRA7 and GRA12 proteins using PLGA NPs as a delivery system. Data represent mean ± SD, n = 3 experiments.CC BY · PubMed Central
Figure 4 Specific antibody responses in mice immunized with Alum+GRA7, PLGA+GRA7, Alum+GRA12, PLGA+GRA12, PBS, Alum, and PLGA. (A) IgG secretion levels. (B) IgG1 secretion levels. (C) IgG2a secretion levels. (D) Levels of IgG1 and IgG2a. Results are represented as 450 nm optical density means ± SD. *p< 0.05, **p< 0.01, ***p< 0.001.
Figure 4 Specific antibody responses in mice immunized with Alum+GRA7, PLGA+GRA7, Alum+GRA12, PLGA+GRA12, PBS, Alum, and PLGA. (A) IgG secretion levels. (B) IgG1 secretion levels. (C) IgG2a secretion levels. (D) Levels of IgG1 and IgG2a. Results are represented as 450 nm optical density means ± SD. *p< 0.05, **p< 0.01, ***p< 0.001.CC BY · PubMed Central
Figure 5 Lymphocyte proliferation was evaluated 5 weeks after the last immunization. Five weeks after the last immunization spleens were collected and lymphocyte proliferation responses were assessed. Results represent 450-nm optical density means ± SD. *p< 0.05, ***p< 0.001.
Figure 5 Lymphocyte proliferation was evaluated 5 weeks after the last immunization. Five weeks after the last immunization spleens were collected and lymphocyte proliferation responses were assessed. Results represent 450-nm optical density means ± SD. *p< 0.05, ***p< 0.001.CC BY · PubMed Central
Figure 6 Splenocyte cytokine production after T. gondii lysate TLA stimulation. (A) IFN-γ. (B) IL-4. (C) IL-10. Three mice from each group were analyzed. Data represent means ± SD of three independent experiments. *p< 0.05, **p< 0.01, ***p< 0.001.
Figure 6 Splenocyte cytokine production after T. gondii lysate TLA stimulation. (A) IFN-γ. (B) IL-4. (C) IL-10. Three mice from each group were analyzed. Data represent means ± SD of three independent experiments. *p< 0.05, **p< 0.01, ***p< 0.001.CC BY · PubMed Central
Figure 7 Parasite loads were analyzed using SYBR-green quantification real-time PCR. Heart, liver, lung, and spleen tissues were collected when symptoms of T. gondii infection became evident, and parasite loads were evaluated. (A) Parasite loads in the heart. (B) Parasite loads in the liver. (C) Parasite loads in the lung. (D) Parasites loads in the spleen. Data are presented as means ± SD of three independent experiments. *p<0.05, **p< 0.01, ***p<0.001.
Figure 7 Parasite loads were analyzed using SYBR-green quantification real-time PCR. Heart, liver, lung, and spleen tissues were collected when symptoms of T. gondii infection became evident, and parasite loads were evaluated. (A) Parasite loads in the heart. (B) Parasite loads in the liver. (C) Parasite loads in the lung. (D) Parasites loads in the spleen. Data are presented as means ± SD of three independent experiments. *p<0.05, **p< 0.01, ***p<0.001.CC BY · PubMed Central
Figure 8 Survival curves of immunized BALB/c mice after T. gondii challenge. Mice were challenged with 1 × 103 T. gondii RH strain tachyzoites 5 weeks after the final immunization (n = 10 per group).
Figure 8 Survival curves of immunized BALB/c mice after T. gondii challenge. Mice were challenged with 1 × 103 T. gondii RH strain tachyzoites 5 weeks after the final immunization (n = 10 per group).CC BY · PubMed Central

Verification

Claims the paper makes

2 Valid · 0 Not valid · 3 Not checked · 51 Own results and interpretations

35 more claims

Create a free account to see all 56 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 13
  • Probably not a substantial claim. 4
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 58 references

Cited by

See all 22

Metadata

Authors
Sun, H.-C., Deng, P.-M., Fu, Y., Deng, J.-H., Xie, R.-H., Huang, J., Qi, M., & Shi, T.-Y.
Affiliations
  • Xinjiang Production and Construction Corps (CN)
  • ZheJiang Academy of Agricultural Sciences (CN)
Corresponding author
Qi, Meng
Venue
Frontiers in Cellular and Infection Microbiology
Published
2023-07-12
Volume
13
Pages
1209755-1209755
ISSN
2235-2988 (ISSN-L)
OpenAlex
W4384023864
Cited by
22
References
61
Citations by year
2026: 8 · 2025: 6 · 2024: 8
FWCI
5.09
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Cellular and Infection Microbiology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (31802183, 32072883)
Topics
  • Life Sciences › Immunology and Microbiology › Parasitology › Toxoplasma gondii Research Studies
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Coccidia and coccidiosis research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
Toxoplasma gondii, toxoplasmosis vaccine, PLGA nanoparticles, GRA7, recombinant protein vaccine, Th1 response, IgG2a, infection intensity, nanoparticle vaccine delivery
MeSH terms
Alum Compounds, Animals, Antibodies, Protozoan, Antigens, Protozoan, Humans, Mice, Inbred BALB C, Recombinant Proteins, Toxoplasma, Toxoplasmosis, Protozoan Proteins, Protozoan Vaccines, Lactic Acid, Mice, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Protective efficacy of Toxoplasma gondii GRA12 or GRA7 recombinant proteins encapsulated in PLGA nanoparticles against acute Toxoplasma gondii infection in mice. https://app.cochat.ai/papers/10.3389/fcimb.2023.1209755
The paper
Sun, H.-C., Deng, P.-M., Fu, Y., Deng, J.-H., Xie, R.-H., Huang, J., Qi, M., & Shi, T.-Y. (2023). Protective efficacy of Toxoplasma gondii GRA12 or GRA7 recombinant proteins encapsulated in PLGA nanoparticles against acute Toxoplasma gondii infection in mice. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2023.1209755

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.